Objective: Significant efforts are currently being made to identify novel biomarkers for the
diagnosis and risk stratification of prostate cancer (PCa). Metabolomics can be a very useful …

Abstract Introduction Prostate cancer (PCa) is one of the most common malignancies in men
worldwide. Serum prostate specific antigen (PSA) level has been extensively used as a …

Purpose Currently, there are no accurate markers for predicting potentially lethal prostate
cancer (PC) before biopsy. This study aimed to develop urine tests to predict clinically …

Abstract Background Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are
prevalent conditions affecting a significant portion of the male population, particularly with …

Despite continuing research for precise probing and grading of prostate cancer (PC)
biomarkers, the indexes lack sensitivity and specificity. To search for PC biomarkers, we …

Background Prostate cancer (PC) is a heterogenous multifocal disease ranging from
indolent to lethal states. For improved treatment-stratification, reliable approaches are …

Abstract Objective Prostate cancer (PCa) is one of the most commonly diagnosed cancers
among men which is associated with profound metabolic changes. Systematic analysis of …

The prostate has long been known to exhibit unique metabolite profiles. In the last decade,
advances in nuclear magnetic resonance spectroscopy and mass spectrometry have been …

Background: An individualised risk-stratified screening for prostate cancer (PCa) would
select the patients who will benefit from further investigations as well as therapy. Current …

Objective: Prostate cancer (PCa) is the second most common male malignancy globally.
Prostate-specific antigen (PSA) is an important biomarker for PCa diagnosis. However, it is …